Rivaroxaban — Drug Intelligence | 32 EU Trials

Filter these 32 trials by condition, phase, country and more.

Open in Search →

32 Registered trials

18 Recruiting

10 Completed trials

28 Sponsors

18 Countries

Phase III

Phase II

Phase IV

Phase III: 9 Phase II/III: 1 Phase II: 4 Phase III/IV: 3 Phase IV: 15

Oversight events:

3 temporary halts 1 unexpected event 5 corrective measures across 3 trials

View oversight register →

Indications tested

Atrial fibrillation 7 Embolic stroke 1 Acute coronary syndrome 1 Atrial flutter 1 Chronic coronary syndrome 1 Pulmonary embolism 1 Joint stabilisation 1 Aortic valve stenosis 1 Cardiac ablation 1 Ischaemic stroke 1 Aortic stenosis 1 Behcet's syndrome 1

Sponsors using this IMP

Assistance Publique Hopitaux De Paris 2 Hamilton Health Sciences Corporation 2 Insel Gruppe AG 2 Oslo University Hospital HF 2 Rigshospitalet 2 Academisch Ziekenhuis Leiden 1 Amsterdam UMC 1 Amsterdam UMC Stichting 1 Anthos Therapeutics Inc. 1 Bispebjerg Hospital 1 Celgene Corp. 1 Centre Hospitalier De Pau 1

All trials

32 total

Apixaban/rivaroxaban Versus Aspirin for primary prevention of thrombo-embolic complications in JAK2V617F-positive myeloproliferative neoplas… Pending

2024-515362-13-00 Phase II/III 1 country Centre Hospitalier Regional Et Universitaire De Brest
Stabilization of vulnerable atherosclerotic carotid plaques by Rivaroxaban as evaluated by 3D contrast enhanced ultrasound (CEUS) Pending

2024-518539-13-00 Phase III/IV 1 country Rigshospitalet
Anticoagulant medicines for Balloon Pulmonary Angioplasty Pending

2024-518803-23-00 Phase IV 1 country St. Antonius Ziekenhuis
Short-Term Anticoagulation versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure. The ANDES s… Pending

2025-520954-12-00 Phase IV 1 country Centre Hospitalier Universite De Laval
EvaluaTion of Clinical and laboratory outcomes of Rivaroxaban in short Bowel syndrome patients dEpending on Long term parenteral nutrition: … Recruiting

2024-519078-38-00 Phase IV 1 country Amsterdam UMC Stichting
Treatment of heart and blood vessel disease (cardiovascular disease) with low dose blood thinner (low dose rivaroxaban) in people with advan… Recruiting

2024-512483-59-00 Phase III 3 countries The George Institute For Global Health
Platelet inhibition versus direct oral anticoagulation in patients undergoing percutaneous closure of patent foramen ovale or atrial septal … Recruiting

2024-517115-70-00 Phase II 1 country Sint Antonius Ziekenhuis Stichting
Clinical Surveillance vs. Anticoagulation for Low-risk Patients with Isolated Subsegmental Pulmonary Embolism: A Multicenter Randomized Plac… Recruiting

2023-507801-32-00 Phase IV 3 countries Insel Gruppe AG
LA-HCM : Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients with Abnormal Left Atrial Strain : A Randomized M… Recruiting

2024-511084-28-00 Phase III/IV 1 country Centre Hospitalier Universitaire De Rennes
Randomized controlled multicenter study comparing steroid therapy plus anticoagulants to steroid therapy alone in deep venous thrombosis of … Recruiting

2023-510262-27-00 Phase II 1 country Assistance Publique Hopitaux De Paris
Thrombolysis in Factor Xa-inhibitors Trial (SIFT) Recruiting

2023-509907-34-01 Phase III 3 countries Oslo University Hospital HF
Chronic anticoagulation in end-stage renal disease patients: pharmacocinetics and pharmacodynamic of a reduced dose regimen of rivaroxaban (… Recruiting

2023-505733-28-00 Phase II 1 country Centre Hospitalier Regional Universitaire De Tours
Treatment with a single drug that prevents blood clot formation followed by an anticoagulant drug in patients with irregular heartbeat who h… Recruiting

2023-509717-36-00 Phase III 7 countries Insel Gruppe AG
ENhanced recovery and ABbreviated LEngth of Anticoagulation for Thromboprophylaxis after primary Hip Arthroplasty Recruiting

2023-507490-18-00 Phase III 2 countries Universitaetsmedizin Der Johannes Gutenberg-Universitaet Mainz Koerperschaft Des…
The Direct Oral Anticoagulation versus Vitamin K Antagonist after Cardiac Surgery (DANCE) Trial Recruiting

2023-504504-28-00 Phase III 1 country Hamilton Health Sciences Corporation
DISTINCT: inDividual, targeted thrombosIS prophylaxis versus the standard ‘one size fits all’ approach in patients undergoing Total hIp or t… Recruiting

2023-510186-98-00 Phase IV 1 country Academisch Ziekenhuis Leiden
RIVACAST - RIVAroxaban versus low-molecular weight heparin in patients with lower limb trauma requiring brace or CASTing Recruiting

2023-509905-62-00 Phase III 1 country Centre Hospitalier Universitaire D'Angers
Can patients with atrial fibrillation discontinue anticoagulant therapy after cardiac surgery: The ATLAAC trial Recruiting

2022-502986-92-00 Phase IV 2 countries Odense University Hospital
Anticoagulation for Stroke Prevention In patients with Recent Episodes of Atrial Fibrillation occurring transiently with stress Recruiting

2023-509142-35-00 Phase IV 10 countries Hamilton Health Sciences Corporation
Iberdomide Manteinance Versus Lenalidomide Manteinance Therapy Following Autologous Stem Cell Transplant in Participants with NDMM Recruiting

2022-501515-14-00 Phase III 16 countries Celgene Corp.
Best Antithrombotic Therapy in patients with acute Venous ThromboEmbolism while taking antiplatelets: the BAT-VTE Recruiting

2022-500974-33-00 Phase III 1 country Centre Hospitalier Universitaire De Saint Etienne
Preventing formation of blood clots due to atrial fibrillation, a cardiac arrhythmia that first occurred after coronary bypass surgery, with… Recruiting

2024-515924-35-00 Phase IV 1 country Icahn School Of Medicine At Mount Sinai
Management of Anticoagulant Therapy monitored by an implantable device with telecardiology in patients with Acute Coronary Syndrome associat… Ended

2024-515433-15-02 Phase IV 1 country Centre Hospitalier De Pau
Rivaroxaban Monotherapy and CYP2C19 Genotype Testing in Patients with Atrial Fibrillation and Percutaneous Coronary Intervention Ended

2023-508904-39-00 Phase IV 1 country Amsterdam UMC

Showing 1–24 of 32 trials

← All drugs A–Z